|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wright JD, Barrena Medel NI, Sehouli J,
Fujiwara K and Herzog TJ: Contemporary management of endometrial
cancer. Lancet. 379:1352–1360. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Salvesen HB, Haldorsen IS and Trovik J:
Markers for individualised therapy in endometrial carcinoma. Lancet
Oncol. 13:e353–e361. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Asghar U, Witkiewicz AK, Turner NC and
Knudsen ES: The history and future of targeting cyclin-dependent
kinases in cancer therapy. Nat Rev Drug Discov. 14:130–146. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sherr CJ, Beach D and Shapiro GI:
Targeting CDK4 and CDK6: From discovery to therapy. Cancer Discov.
6:353–367. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Witkiewicz AK, Knudsen KE, Dicker AP and
Knudsen ES: The meaning of p16ink4a expression in
tumors: Functional significance, clinical associations and future
developments. Cell Cycle. 10:2497–2503. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Halperin R, Zehavi S, Habler L, Hadas E,
Bukovsky I and Schneider D: Comparative immunohistochemical study
of endometrioid and serous papillary carcinoma of endometrium. Eur
J Gynaecol Oncol. 22:122–126. 2001.PubMed/NCBI
|
|
8
|
Yemelyanova A, Ji H, Shih IeM, Wang TL, Wu
LS and Ronnett BM: Utility of p16 expression for distinction of
uterine serous carcinomas from endometrial endometrioid and
endocervical adenocarcinomas: Immunohistochemical analysis of 201
cases. Am J Surg Pathol. 33:1504–1514. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen W, Husain A, Nelson GS, Rambau PF,
Liu S, Lee CH, Lee S, Duggan MA and Köbel M: Immunohistochemical
profiling of endometrial serous carcinoma. Int J Gynecol Pathol.
36:128–139. 2017.PubMed/NCBI
|
|
10
|
Chen YW, Chu HC, Ze-Shiang Lin, Shiah WJ,
Chou CP, Klimstra DS and Lewis BC: p16 Stimulates CDC42-dependent
migration of hepatocellular carcinoma cells. PLoS One.
8:e693892013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
McLaughlin-Drubin ME, Park D and Munger K:
Tumor suppressor p16INK4A is necessary for survival of
cervical carcinoma cell lines. Proc Natl Acad Sci USA.
110:16175–16180. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pauck A, Lener B, Hoell M, Kaiser A,
Kaufmann AM, Zwerschke W and Jansen-Dürr P: Depletion of the cdk
inhibitor p16INK4a differentially affects proliferation
of established cervical carcinoma cells. J Virol. 88:5256–5262.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Romagosa C, Simonetti S, Lopez-Vicente L,
Mazo A, Lleonart ME, Castellvi J and Ramon y Cajal S:
p16Ink4a overexpression in cancer: A tumor suppressor
gene associated with senescence and high-grade tumors. Oncogene.
30:2087–2097. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
McLaughlin-Drubin ME, Crum CP and Munger
K: Human papillomavirus E7 oncoprotein induces KDM6A and KDM6B
histone demethylase expression and causes epigenetic reprogramming.
Proc Natl Acad Sci USA. 108:2130–2135. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Junttila TT, Akita RW, Parsons K, Fields
C, Lewis Phillips GD, Friedman LS, Sampath D and Sliwkowski MX:
Ligand-independent HER2/HER3/PI3K complex is disrupted by
trastuzumab and is effectively inhibited by the PI3K inhibitor
GDC-0941. Cancer Cell. 15:429–440. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu P, Cheng H, Santiago S, Raeder M,
Zhang F, Isabella A, Yang J, Semaan DJ, Chen C, Fox EA, et al:
Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K
pathway-dependent and PI3K pathway-independent mechanisms. Nat Med.
17:1116–1120. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Juvekar A, Burga LN, Hu H, Lunsford EP,
Ibrahim YH, Balmana J, Rajendran A, Papa A, Spencer K, Lyssiotis
CA, et al: Combining a PI3K inhibitor with a PARP inhibitor
provides an effective therapy for BRCA1-related breast cancer.
Cancer Discov. 2:1048–1063. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee GY, Kenny PA, Lee EH and Bissell MJ:
Three-dimensional culture models of normal and malignant breast
epithelial cells. Nat Methods. 4:359–365. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li L, Chang W, Yang G, Ren C, Park S,
Karantanos T, Karanika S, Wang J, Yin J, Shah PK, et al: Targeting
poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage
response pathway in castration-resistant prostate cancer. Sci
Signal. 7:ra472014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xiao Y, Wang J, Qin Y, Xuan Y, Jia Y, Hu
W, Yu W, Dai M, Li Z, Yi C, et al: Ku80 cooperates with CBP to
promote COX-2 expression and tumor growth. Oncotarget. 6:8046–8061.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Morton CL and Houghton PJ: Establishment
of human tumor xenografts in immunodeficient mice. Nat Protoc.
2:247–250. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang D, Li C, Zhang Y, Wang M, Jiang N,
Xiang L, Li T, Roberts TM, Zhao JJ, Cheng H, et al: Combined
inhibition of PI3K and PARP is effective in the treatment of
ovarian cancer cells with wild-type PIK3CA genes. Gynecol
Oncol. 142:548–556. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Netzer IM, Kerner H, Litwin L, Lowenstein
L and Amit A: Diagnostic implications of p16 expression in serous
papillary endometrial cancer. Int J Gynecol Cancer. 21:1441–1445.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Han G, Sidhu D, Duggan MA, Arseneau J,
Cesari M, Clement PB, Ewanowich CA, Kalloger SE and Köbel M:
Reproducibility of histological cell type in high-grade endometrial
carcinoma. Modern Pathol. 26:1594–1604. 2013. View Article : Google Scholar
|
|
26
|
Cancer Genome Atlas Research Network, ;
Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H,
Robertson AG, Pashtan I, Shen R, Benz CC, et al: Integrated genomic
characterization of endometrial carcinoma. Nature. 497:67–73. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Konecny GE, Winterhoff B, Kolarova T, Qi
J, Manivong K, Dering J, Yang G, Chalukya M, Wang HJ, Anderson L,
et al: Expression of p16 and retinoblastoma determines response to
CDK4/6 inhibition in ovarian cancer. Clin Cancer Res. 17:1591–1602.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Groves IJ, Knight EL, Ang QY, Scarpini CG
and Coleman N: HPV16 oncogene expression levels during early
cervical carcinogenesis are determined by the balance of epigenetic
chromatin modifications at the integrated virus genome. Oncogene.
35:4773–4786. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Soto DR, Barton C, Munger K and
McLaughlin-Drubin ME: KDM6A addiction of cervical carcinoma cell
lines is triggered by E7 and mediated by p21CIP1
suppression of replication stress. PLoS Pathog. 13:e10066612017.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhao N, Ang MK, Yin XY, Patel MR, Fritchie
K, Thorne L, Muldrew KL, Hayward MC, Sun W, Wilkerson MD, et al:
Different cellular p16INK4a localisation may signal
different survival outcomes in head and neck cancer. Br J Cancer.
107:482–490. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Di Vinci A, Perdelli L, Banelli B, Salvi
S, Casciano I, Gelvi I, Allemanni G, Margallo E, Gatteschi B and
Romani M: p16INK4a promoter methylation and protein
expression in breast fibroadenoma and carcinoma. Int J Cancer.
114:414–421. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gray-Schopfer VC, Cheong SC, Chong H, Chow
J, Moss T, Abdel-Malek ZA, Marais R, Wynford-Thomas D and Bennett
DC: Cellular senescence in naevi and immortalisation in melanoma: A
role for p16? Br J Cancer. 95:496–505. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hashizume R, Andor N, Ihara Y, Lerner R,
Gan H, Chen X, Fang D, Huang X, Tom MW, Ngo V, et al: Pharmacologic
inhibition of histone demethylation as a therapy for pediatric
brainstem glioma. Nat Med. 20:1394–1396. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cregan S, Breslin M, Roche G, Wennstedt S,
MacDonagh L, Albadri C, Gao Y, O'Byrne KJ, Cuffe S, Finn SP, et al:
Kdm6a and Kdm6b: Altered expression in malignant pleural
mesothelioma. Int J Oncol. 50:1044–1052. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Morozov VM, Li Y, Clowers MM and Ishov AM:
Inhibitor of H3K27 demethylase JMJD3/UTX GSK-J4 is a potential
therapeutic option for castration resistant prostate cancer.
Oncotarget. 8:62131–62142. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kruidenier L, Chung CW, Cheng Z, Liddle J,
Che K, Joberty G, Bantscheff M, Bountra C, Bridges A, Diallo H, et
al: A selective jumonji H3K27 demethylase inhibitor modulates the
proinflammatory macrophage response. Nature. 488:404–408. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wu W, Qin M, Jia W, Huang Z, Li Z, Yang D,
Huang M, Xiao C, Long F, Mao J, et al: Cystathionine-γ-lyase
ameliorates the histone demethylase JMJD3-mediated autoimmune
response in rheumatoid arthritis. Cell Mol Immunol. May
29–2018.(Epub ahead of print). doi: 10.1038/s41423-018-0037-8.
View Article : Google Scholar
|
